# Study of Novel Treatment Combinations in Patients With Lung Cancer

> **NCT05633667** · PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 270 (estimated)

## Conditions studied

- Lung Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Zimberelimab (ZIM)
- **DRUG:** Domvanalimab (DOM)
- **DRUG:** Sacituzumab govitecan-hziy (SG)
- **DRUG:** Etrumadenant (ETRUMA)
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05633667
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633667, "Study of Novel Treatment Combinations in Patients With Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05633667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*